[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitochondrial-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitochondrial-diabetes":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100650329","coq10-effects-on-mdm-liver-fat-via-fibrotouchi-100650329",false,"NCT07748130","CoQ10 Effects on MDM Liver Fat Via FibroTouchI.","The Effect of Coenzyme Q10 on Quantitative Changes in Hepatic Fat in Patients With Mitochondrial Diabetes","1\\. Mitochondrial Diabetes Group\n\nInclusion Criteria:\n\n1. Confirmed as a carrier of the mitochondrial DNA m.3243A\\>G mutation through genetic testing;\n2. Meeting the diagnostic criteria for diabetes (WHO 1999 diagnostic criteria);\n3. Aged between 18 and 70 years;\n4. Willing to participate and having signed the informed consent form.\n\nExclusion Criteria:\n\n1. Type 1 or type 2 diabetes (not caused by mitochondrial gene mutations);\n2. Comorbid with viral hepatitis, drug-induced hepatitis, alcoholic liver disease, Wilson's disease, or other specific diseases that can lead to fatty liver;\n3. Severe cardiac, pulmonary, or renal insufficiency;\n4. Pregnant or lactating women;\n5. Having used coenzyme Q10 or other mitochondrial-targeted drugs within the past 3 months;\n6. Having contraindications to MRI examination;\n7. Having experienced infection, surgery, or major trauma within the past 4 weeks.\n\nWithdrawal\u002FDropout Criteria:\n\n1. The subject withdraws informed consent;\n2. The occurrence of serious adverse events;\n3. Loss to follow-up;\n4. Medication adherence that continued participation in \\\u003C 80%;\n5. The researcher believes the study is not in the best interest of the subject. 2. Type 1 Diabetes Control Group\n\nInclusion Criteria:\n\n1. Meeting the diagnostic criteria for type 1 diabetes, with positive islet autoantibodies (GAD, IA-2, ICA, etc.);\n2. Aged between 18 and 70 years;\n3. Willing to participate and having signed the informed consent form.\n\nExclusion Criteria:\n\nSame as the exclusion criteria (1) to (7) for the mitochondrial diabetes group. 3. Healthy Adult Control Group\n\nInclusion Criteria:\n\n1. No history of diabetes, with fasting blood glucose \\\u003C 5.6 mmol\u002FL and HbA1c \\\u003C 5.7%;\n2. Aged between 18 and 70 years;\n3. Willing to participate and having signed the informed consent form.\n\nExclusion Criteria:\n\nSame as the exclusion criteria (1) to (7) for the mitochondrial diabetes group.",true,"ALL","18 Years","70 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","Mitochondrial diabetes mellitus (MDM) is a rare subtype of diabetes caused by mitochondrial dysfunction, often accompanied by hepatic steatosis. Coenzyme Q10 (CoQ10), a key electron carrier and antioxidant, may improve mitochondrial function and lipid metabolism. This prospective study aims to evaluate the effect of 12-week CoQ10 supplementation (300 mg\u002Fday) on liver fat content (assessed by FibroTouch CAP ) in MDM patients with m.3243A\\>G mutation. An exploratory case-control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls. This study is the first to explore the link between mitochondrial defects and hepatic fat accumulation specifically in MDM, and to test CoQ10 as a potential therapy, offering new insights for both MDM and MAFLD management.",[28],"Mitochondrial Diabetes","NOT_YET_RECRUITING","2026-07-31",{"date":32,"type":33},"2026-08-05","ACTUAL",{"date":35,"type":22},"2026-09",{"date":37,"type":22},"2027-12",{"name":39,"class":40},"The 95th Hospital of Putian，Putian, Fujian, China","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":41},"100361639","monogenic-diabetes-misdiagnosed-as-type-1-100361639","NCT03988764","Monogenic Diabetes Misdiagnosed as Type 1","Accurate Diagnosis of Diabetes for Appropriate Management","ADDAM","Inclusion Criteria:\n\n* Diagnosis of diabetes under the age of 25 as either type 1 or undetermined type.\n\nExclusion Criteria:\n\n* Existing T1D autoantibody testing with a positive result","1 Day","25 Years",{"count":53,"type":22},5000,"OBSERVATIONAL","The study has two aims:\n\n1. To (1a) determine the frequency of monogenic diabetes misdiagnosed as type 1 diabetes (T1D) and (2) to define an algorithm for case selection.\n2. To discover novel genes whose mutations cause monogenic diabetes misdiagnosed as T1D.",[57,58,59,60,61,62,28],"Diabetes Mellitus, Type 1","Monogenic Diabetes","Neonatal Diabetes","Maturity-onset Diabetes in the Young (MODY)","Wolfram Syndrome","Wolcott-Rallison Syndrome","RECRUITING","2024-12-06",{"date":66,"type":33},"2024-12-10",{"date":68,"type":33},"2019-09-24",{"date":70,"type":22},"2025-12-31",{"name":72,"class":40},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre"]